TOCA - Tocagen Stock Price, News & Analysis

$10.11 0.11 (1.10 %)
(As of 11/22/2017 04:00 PM ET)
Previous Close$10.00
Today's Range$9.91 - $10.23
52-Week Range$8.60 - $17.95
Volume130,433 shs
Average Volume144,652 shs
Market Capitalization$201.66 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Tocagen (NASDAQ:TOCA)

Tocagen logoTocagen Inc. (Tocagen) is a clinical-stage, cancer-selective gene therapy company. The Company is focused on developing product candidates designed to activate a patient’s immune system against their own cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to selectively deliver therapeutic genes into the deoxyribonucleic acid (DNA) of cancer cells. Its lead product candidates are vocimagene amiretrorepvec (Toca 511) and flucytosine extended release (Toca FC). Toca 511 is an investigational injectable retroviral replicating vector (RRV) that encodes a prodrug activator enzyme, cytosine deaminase (CD). Toca FC is an investigational extended-release version of 5-fluorocytosine (5-FC), a prodrug that is inactive as an anti-cancer drug. As of February, 2017, Tocagen has completed enrollment of the Phase II portion with 187 patients.


Industry, Sector and Symbol:
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Sector: Medical
  • Symbol: NASDAQ:TOCA
  • CUSIP: N/A
  • Web: www.tocagen.com
Debt:
  • Debt-to-Equity Ratio: 0.07%
  • Current Ratio: 6.03%
  • Quick Ratio: 6.03%
Sales & Book Value:
  • Annual Sales: $40,000.00
  • Price / Sales: 5,006.98
  • Book Value: $4.04 per share
  • Price / Book: 2.50
Profitability:
  • Net Income: $-33,470,000.00
  • Net Margins: -89,078.05%
  • Return on Assets: -51.70%
Misc:
  • Employees: 61
  • Outstanding Shares: 19,810,000
 

Frequently Asked Questions for Tocagen (NASDAQ:TOCA)

What is Tocagen's stock symbol?

Tocagen trades on the NASDAQ under the ticker symbol "TOCA."

How were Tocagen's earnings last quarter?

Tocagen Inc (NASDAQ:TOCA) released its earnings results on Wednesday, November, 8th. The company reported ($0.50) EPS for the quarter, missing analysts' consensus estimates of ($0.48) by $0.02. The firm had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.01 million. View Tocagen's Earnings History.

When will Tocagen make its next earnings announcement?

Tocagen is scheduled to release their next quarterly earnings announcement on Wednesday, February, 14th 2018. View Earnings Estimates for Tocagen.

Where is Tocagen's stock going? Where will Tocagen's stock price be in 2017?

2 brokers have issued 12-month price targets for Tocagen's shares. Their predictions range from $19.00 to $28.00. On average, they anticipate Tocagen's stock price to reach $23.67 in the next year. View Analyst Ratings for Tocagen.

Are investors shorting Tocagen?

Tocagen saw a decrease in short interest in the month of October. As of October 13th, there was short interest totalling 490,006 shares, a decrease of 37.5% from the September 29th total of 783,892 shares. Based on an average trading volume of 125,307 shares, the days-to-cover ratio is presently 3.9 days. Currently, 2.9% of the shares of the company are short sold.

Who are some of Tocagen's key competitors?

Who are Tocagen's key executives?

Tocagen's management team includes the folowing people:

  • Faheem Hasnain, Independent Chairman of the Board (Age 58)
  • Martin J. Duvall, Chief Executive Officer, Director (Age 54)
  • Mark G. Foletta CPA, Chief Financial Officer, Executive Vice President (Age 55)
  • Harry E. Gruber M.D., President - Science and Innovation, Director (Age 64)
  • Dennis N. Berman, Executive Vice President - Corporate Development (Age 65)
  • Douglas Jolly Ph.D., Executive Vice President - Research and Pharmaceutical Development (Age 69)
  • Asha Das M.D., Senior Vice President, Chief Medical Officer (Age 52)
  • Thomas E. Darcy, Director (Age 66)
  • Franklin M. Berger, Independent Director (Age 67)
  • Lori A. Kunkel M.D., Independent Director (Age 59)

When did Tocagen IPO?

(TOCA) raised $80 million in an IPO on Thursday, April 13th 2017. The company issued 7,300,000 shares at $10.00-$12.00 per share. Leerink Partners, Evercore ISI and Stifel acted as the underwriters for the IPO.

When did the company's lock-up period expire?

Tocagen's lock-up period expired on Tuesday, October 10th. Tocagen had issued 8,500,000 shares in its public offering on April 13th. The total size of the offering was $85,000,000 based on an initial share price of $10.00. Since the expiration of the company's lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company have been lifted.

Who owns Tocagen stock?

Tocagen's stock is owned by many different of institutional and retail investors. Top institutional investors include JPMorgan Chase & Co. (3.18%), Nicholas Investment Partners LP (0.25%), Granahan Investment Management Inc. MA (0.16%) and BBR Partners LLC (0.07%). Company insiders that own Tocagen stock include Asha Das, Harry E Gruber, Mark G Foletta and Paul Schimmel. View Institutional Ownership Trends for Tocagen.

Who sold Tocagen stock? Who is selling Tocagen stock?

Tocagen's stock was sold by a variety of institutional investors in the last quarter, including Nicholas Investment Partners LP. View Insider Buying and Selling for Tocagen.

Who bought Tocagen stock? Who is buying Tocagen stock?

Tocagen's stock was acquired by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Granahan Investment Management Inc. MA and BBR Partners LLC. Company insiders that have bought Tocagen stock in the last two years include Asha Das, Harry E Gruber, Mark G Foletta and Paul Schimmel. View Insider Buying and Selling for Tocagen.

How do I buy Tocagen stock?

Shares of Tocagen can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Tocagen's stock price today?

One share of Tocagen stock can currently be purchased for approximately $10.11.

How big of a company is Tocagen?

Tocagen has a market capitalization of $201.66 million and generates $40,000.00 in revenue each year. Tocagen employs 61 workers across the globe.

How can I contact Tocagen?

Tocagen's mailing address is 3030 BUNKER HILL STREET SUITE 230, SAN DIEGO CA, 92109. The company can be reached via phone at 858-412-8400 or via email at [email protected]


MarketBeat Community Rating for Tocagen (TOCA)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  57 (Vote Outperform)
Underperform Votes:  65 (Vote Underperform)
Total Votes:  122
MarketBeat's community ratings are surveys of what our community members think about Tocagen and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Tocagen (NASDAQ:TOCA)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 0 Hold Ratings, 2 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $23.67 (134.09% upside)

Consensus Price Target History for Tocagen (NASDAQ:TOCA)

Price Target History for Tocagen (NASDAQ:TOCA)

Analysts' Ratings History for Tocagen (NASDAQ:TOCA)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/25/2017Stifel NicolausReiterated RatingBuy$24.00LowView Rating Details
5/15/2017Leerink SwannInitiated CoverageMkt Perform$19.00MediumView Rating Details
5/9/2017Evercore ISIReiterated RatingOutperform$28.00LowView Rating Details
(Data available from 11/22/2015 forward)

Earnings

Earnings History and Estimates Chart for Tocagen (NASDAQ:TOCA)

Earnings by Quarter for Tocagen (NASDAQ:TOCA)

Earnings History by Quarter for Tocagen (NASDAQ TOCA)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/14/2018        
11/8/2017Q3 2017($0.48)($0.50)$0.01 million$0.01 millionViewN/AView Earnings Details
8/9/2017Q2($0.52)($0.56)$0.01 million$0.01 millionViewN/AView Earnings Details
5/23/2017Q1 2017($2.70)($4.11)$0.01 million$0.01 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Tocagen (NASDAQ:TOCA)
2017 EPS Consensus Estimate: ($6.89)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($4.93)($4.93)($4.93)
Q2 20171($0.57)($0.57)($0.57)
Q3 20171($0.67)($0.67)($0.67)
Q4 20171($0.72)($0.72)($0.72)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Tocagen (NASDAQ:TOCA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Tocagen (NASDAQ TOCA)

Institutional Ownership Percentage: 38.25%
Insider Trades by Quarter for Tocagen (NASDAQ:TOCA)
Insider Trades by Quarter for Tocagen (NASDAQ:TOCA)

Insider Trades by Quarter for Tocagen (NASDAQ TOCA)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
4/19/2017Asha DasSVPBuy2,500$10.00$25,000.00View SEC Filing  
4/19/2017Harry E GruberInsiderBuy25,000$10.00$250,000.00View SEC Filing  
4/19/2017Mark G FolettaCFOBuy5,000$10.00$50,000.00View SEC Filing  
4/19/2017Paul SchimmelDirectorBuy10,000$10.00$100,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Tocagen (NASDAQ TOCA)

Source:
DateHeadline
Tocagen Announces Time Change for Presentation at Evercore ISI Biopharma Catalyst/Deep Dive ConferenceTocagen Announces Time Change for Presentation at Evercore ISI Biopharma Catalyst/Deep Dive Conference
finance.yahoo.com - November 22 at 12:15 PM
Zacks: Brokerages Set $23.67 Price Target for Tocagen Inc (TOCA)Zacks: Brokerages Set $23.67 Price Target for Tocagen Inc (TOCA)
www.americanbankingnews.com - November 15 at 5:06 AM
Tocagen to Present at Two Investor Conferences in NovemberTocagen to Present at Two Investor Conferences in November
finance.yahoo.com - November 10 at 9:19 AM
Tocagen Inc (TOCA) Issues Quarterly  Earnings ResultsTocagen Inc (TOCA) Issues Quarterly Earnings Results
www.americanbankingnews.com - November 9 at 7:48 PM
Tocagen Reports Third Quarter 2017 Financial and Business ResultsTocagen Reports Third Quarter 2017 Financial and Business Results
finance.yahoo.com - November 9 at 8:18 AM
Tocagen to Present Updated Clinical and Preclinical Data at Three Scientific ConferencesTocagen to Present Updated Clinical and Preclinical Data at Three Scientific Conferences
finance.yahoo.com - November 9 at 8:18 AM
Are Tocagen Inc’s (TOCA) Interest Costs Too High?Are Tocagen Inc’s (TOCA) Interest Costs Too High?
finance.yahoo.com - November 5 at 7:36 AM
Tocagen to Report Third Quarter 2017 Financial Results on Wednesday, November 8Tocagen to Report Third Quarter 2017 Financial Results on Wednesday, November 8
finance.yahoo.com - November 2 at 9:55 AM
TOCAGEN INC (TOCA) Scheduled to Post Quarterly Earnings on WednesdayTOCAGEN INC (TOCA) Scheduled to Post Quarterly Earnings on Wednesday
www.americanbankingnews.com - November 2 at 9:53 AM
Financial Review: Applied Genetic Technologies Corporation (AGTC) versus Tocagen (TOCA)Financial Review: Applied Genetic Technologies Corporation (AGTC) versus Tocagen (TOCA)
www.americanbankingnews.com - October 31 at 11:10 PM
Tocagen Inc (TOCA) Short Interest UpdateTocagen Inc (TOCA) Short Interest Update
www.americanbankingnews.com - October 28 at 2:26 AM
Tocagen (TOCA) to Accelerate Toca 511 and Toca FC Development into Pivotal Phase 3 TrialTocagen (TOCA) to Accelerate Toca 511 and Toca FC Development into Pivotal Phase 3 Trial
www.streetinsider.com - October 27 at 4:32 PM
Tocagen Presents Updated Durable Complete Response Data from Phase 1 Trial of Toca 511 & Toca FC in Recurrent High-Grade GliomaTocagen Presents Updated Durable Complete Response Data from Phase 1 Trial of Toca 511 & Toca FC in Recurrent High-Grade Glioma
finance.yahoo.com - October 27 at 4:32 PM
Tocagen to Accelerate Toca 511 & Toca FC Development into Pivotal Phase 3 TrialTocagen to Accelerate Toca 511 & Toca FC Development into Pivotal Phase 3 Trial
finance.yahoo.com - October 27 at 6:58 AM
Tocagen to Present Updated Durable Response Data from Phase 1 Trial of Toca 511 & Toca FC in Recurrent Brain Cancer at the 2017 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsTocagen to Present Updated Durable Response Data from Phase 1 Trial of Toca 511 & Toca FC in Recurrent Brain Cancer at the 2017 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
finance.yahoo.com - October 17 at 8:11 AM
Tocagen Inc (TOCA) Upgraded by Zacks Investment Research to "Hold"Tocagen Inc (TOCA) Upgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - October 11 at 1:32 PM
Tocagen Enters Oversold Territory (TOCA)Tocagen Enters Oversold Territory (TOCA)
www.thestreet.com - October 7 at 9:13 AM
Tocagen Incs Lock-Up Period Will Expire  on October 10th (NASDAQ:TOCA)Tocagen Inc's Lock-Up Period Will Expire on October 10th (NASDAQ:TOCA)
www.americanbankingnews.com - October 3 at 1:18 AM
 Tocagen Inc (TOCA) Receives Consensus Rating of "Buy" from Brokerages Tocagen Inc (TOCA) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - September 18 at 2:48 PM
 Tocagen Inc (TOCA) Given $23.67 Consensus Target Price by Analysts Tocagen Inc (TOCA) Given $23.67 Consensus Target Price by Analysts
www.americanbankingnews.com - September 14 at 4:36 AM
Tocagen Inc (NASDAQ:TOCA) Releases Quarterly  Earnings Results, Misses Expectations By $0.04 EPSTocagen Inc (NASDAQ:TOCA) Releases Quarterly Earnings Results, Misses Expectations By $0.04 EPS
www.americanbankingnews.com - August 10 at 10:24 PM
Tocagen Reports Second Quarter 2017 Financial and Business ResultsTocagen Reports Second Quarter 2017 Financial and Business Results
finance.yahoo.com - August 10 at 8:52 AM
 Tocagen Inc (NASDAQ:TOCA) Given $23.67 Consensus Target Price by Analysts Tocagen Inc (NASDAQ:TOCA) Given $23.67 Consensus Target Price by Analysts
www.americanbankingnews.com - August 8 at 10:40 PM
 Tocagen Inc (NASDAQ:TOCA) Receives Consensus Recommendation of "Buy" from Brokerages Tocagen Inc (NASDAQ:TOCA) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - August 5 at 4:36 PM
Tocagen Inc (NASDAQ:TOCA) to Release Quarterly Earnings on WednesdayTocagen Inc (NASDAQ:TOCA) to Release Quarterly Earnings on Wednesday
www.americanbankingnews.com - August 3 at 12:06 PM
Tocagen to Report Second Quarter 2017 Financial Results on Wednesday, August 9Tocagen to Report Second Quarter 2017 Financial Results on Wednesday, August 9
finance.yahoo.com - August 3 at 8:00 AM
Short Interest in Tocagen Inc (NASDAQ:TOCA) Decreases By 47.8%Short Interest in Tocagen Inc (NASDAQ:TOCA) Decreases By 47.8%
www.americanbankingnews.com - July 29 at 7:14 AM
Tocagen Inc (NASDAQ:TOCA) Earns "Buy" Rating from Stifel NicolausTocagen Inc (NASDAQ:TOCA) Earns "Buy" Rating from Stifel Nicolaus
www.americanbankingnews.com - July 25 at 9:32 PM
BRIEF-Tocagen receives PRIME designation for Toca 511BRIEF-Tocagen receives PRIME designation for Toca 511
www.reuters.com - July 25 at 7:43 AM
Tocagen Receives European Medicines Agency Priority Medicines (PRIME) Designation for Toca 511 in High Grade GliomaTocagen Receives European Medicines Agency Priority Medicines (PRIME) Designation for Toca 511 in High Grade Glioma
finance.yahoo.com - July 25 at 7:43 AM
 Tocagen Inc (NASDAQ:TOCA) Receives Consensus Rating of "Buy" from Brokerages Tocagen Inc (NASDAQ:TOCA) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - July 21 at 8:32 AM

Social Media

Financials

Chart

Tocagen (NASDAQ TOCA) Chart for Wednesday, November, 22, 2017
Loading chart…

This page was last updated on 11/22/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.